APOBEC3B is a single-stranded DNA cytosine deaminase with beneficial innate antiviral 32 functions. However, misregulated APOBEC3B can also be detrimental by inflicting APOBEC 33 signature C-to-T and C-to-G mutations in genomic DNA of multiple cancer types. 34
INTRODUCTION 65
Genetic diversity is key to virus replication, pathogenesis, and transmission, and particularly for 66 escape from adaptive immune responses in vertebrate species (1) (2) (3) . Each virus has evolved to 67 have an optimized level of genetic diversity for its own unique life cycle, with some viruses 68 having high mutation rates and others much lower mutation rates (4, 5) . Multiple processes 69 contribute to the overall constellation of mutations observed in viral genomes, including 70 nucleotide misincorporation by DNA polymerases during replication (4, 2) . 71
Recently, an APOBEC mutation signature has been reported in multiple DNA tumor 72 viruses, including high-risk human papillomavirus (HPV) types and BK polyomaviruses (6) (7) (8) (9) . 73
Several APOBEC enzymes, including APOBEC3B (A3B), bind 5'--TC dinucleotide motifs in 74 single-stranded DNA and catalyze the hydrolytic conversion cytosine to uracil (10, 11) . Left 75 unrepaired, uracil lesions can serve as templates for new DNA synthesis and directly result in C-76 4 to-T mutations. Alternatively, if the uracil base is excised by cellular uracil DNA glycosylase 2 77 (UNG2), then the resulting abasic site becomes non-instructional and may trigger cellular DNA 78 polymerases to insert an adenine opposite the lesion, except REV1 that tends to incorporate 79 either adenine or cytosine. Thus, APOBEC-catalyzed DNA deamination of 5'-TC motifs results 80 in both C-to-T and C-to-G mutations (a signature frequently expanded to include the 3'-81 nucleobases A and T and referred to in the context of trinucleotide motifs 5'--TCA and 5'--TCT). 82
An additional hallmark of virus mutagenesis by APOBEC enzymes is a bias toward the lagging-83 strand of DNA replication (12) (13) (14) . A likely mechanistic relationship with single-stranded DNA 84 replication intermediates is supported by similar correlations in model yeast and E. coli 85 experiments (15, 16) . 86
Human cells have the potential to express up to nine active DNA cytosine deaminases 87 (AID, APOBEC1, and A3A/B/C/D/F/G/H) (17) (18) (19) (20) . Seven of these enzymes prefer 5'-TC motifs 88 in single-stranded DNA, whereas AID uniquely prefers 5'-RC and APOBEC3G (A3G) 5 A3B is the most likely APOBEC family member to contribute to the mutagenesis and evolution 90 of small DNA tumor viruses because it is specifically upregulated by viral oncoproteins. For 91 high-risk HPV types, the oncoproteins E6 and E7 have been implicated through various 92 pathways (21) (22) (23) (24) . For polyomaviruses including JC, BK, and Merkel cell (JCPyV, BKPyV, 93 MCPyV), the large T-antigen (TAg) induces A3B upregulation (6). Although these viral proteins 94 bear little similarity at the amino acid sequence level, they have considerable functional overlap 95 including RB inactivation by E7 and TAg and TP53 inactivation by E6 and TAg. Here we 96 investigate the molecular mechanism by which polyomaviruses promote the transcriptional 97 upregulation of A3B with results converging on the cellular RB/E2F pathway, which is often 98 deregulated in cancer. 99 induction by polyomaviruses has been shown at the mRNA level by RT-qPCR and at the protein 103 level by immunoblotting in primary renal proximal epithelial cells (RPTECs) (6). To extend 104 these results, immunofluorescent microscopy was used to ask whether polyomavirus infection 105 causes a general pan-nuclear upregulation of A3B enzyme and/or localization to discrete 106 subnuclear regions such as virus replication centers in other relevant cell types. Tenth generation 107 (G10) primary human embryonic kidney (HuK(i)G10) cells were infected with JCPyV (MAD1 108 strain) and analyzed 7 days later by pulse-labeling 15 minutes with EdU and immunofluorescent 109 microscopy. As shown previously (25), infected cells are distinguished by larger nuclei positive 110 for TAg and EdU (representative images in Fig. 1A) . Virus replication centers appear as foci that 111 stain even brighter for these two markers. In comparison, A3B is clearly induced in the nuclear 112 compartment of infected cells but not uninfected cells. A3B staining is broadly nuclear and not 113 obviously co-localizing with EdU-positive virus replication foci. TAg and EdU staining have a 114 strong positive correlation signifying active viral DNA replication, and TAg and A3B show a 115 weaker but still significantly positive correlation ( Fig. 1B-C) . 116
To date, many aspects of A3B regulation and function have been determined using 117 normal-like and cancerous mammary epithelial cell lines, because of direct relevance to cancer 118 and a higher capacity for genetic manipulation over primary cells (26, 27) . To ask whether TAg 119 induces A3B in one of these systems, the normal-like mammary epithelial cell line MCF10A was 120 infected with BKPyV and RT-qPCR was used to quantify A3B mRNA levels over time. As 121 above for early passage human embryonic kidney cells, A3B expression peaked 3 and 5 days 122 6 post-infection with mock-treated cells showing no significant changes ( Fig. 1D) . Thus, together 123 with our prior studies (6), polyomavirus appear to possess a conserved and robust capacity for 124 A3B induction. 125 126
APOBEC3B upregulation by polyomavirus large T-antigen requires the canonical RB-127
interacting motif LXCXE. Based on our previous studies (6), the large (L)TAg of multiple 128 different polyomaviruses triggers upregulation of A3B expression in RPTECs. To investigate the 129 LTAg domains responsible for A3B induction, we tested a naturally occurring splice variant of 130
BKPyV LTAg, known as truncT, which lacks the DNA-binding and helicase domains essential 131 for TP53 neutralization (28-30) (schematic in Fig. 2A) . In parallel, we also assessed derivatives 132 of LTAg and truncT with a disrupted LXCXE motif, which is required for inhibiting the tumor 133 suppressor protein RB, as previously reported using SV40 TAg (31). RPTECs were transduced 134 with lentiviruses expressing an empty multiple cloning site as a negative control, BKPyV LTAg 135 as a positive control, BKPyV truncT, and RB-binding site mutant derivatives, incubated 3 days, 136 and assessed by immunoblotting and fluorescent microscopy. Mock-transduced cells express low 137 levels of A3G, and transduction with empty lentivirus causes a modest increase in this protein 138 and also raises A3B levels to faintly detectable levels ( Fig. 2B) . In contrast, both LTAg and 139 truncT dramatically induce A3B expression, and all induction is eliminated by two amino acid 140 substitutions shown previously to abrogate RB binding in SV40 (LFCHED to LFCHKK) (31) 141 ( Fig. 2B) . Immunofluorescent microscopy images also show truncT-mediated induction of 142 nuclear A3B but not by the RB-binding mutant derivative ( Fig. 2C) . Similar results were 143 obtained for truncT the same RB-binding mutant in the human mammary epithelial cell line 144 MCF10A ( Fig. 2D-E is not required for A3B induction because truncT completely lacks the TP53 binding domain 149 ( Fig. 2) . To further ask whether TP53 inactivation might influence A3B gene expression, we 150 quantified A3B mRNA levels in two cell lines that have been used to study A3B regulation, 151
MCF10A and the human estrogen-receptor positive breast cancer cell line 27, 32, 33) ]. Each cell line was treated with either DMSO or 5 µM nutlin, which is a drug 153 that protects TP53 from MDM2-mediated degradation (34). As controls, mRNA levels were 154 quantified for three genes repressed by TP53 (P21, MDM2, and TP53) and one gene activated by 155 TP53 (7LC7A11). Respectively, the expression of these genes was derepressed or repressed by 156 nutlin treatment ( Fig. 3A-B) . In comparison, neither steady-state nor PMA-induced A3B mRNA 157 levels were changed by nutlin ( Fig. 3A-B) . Moreover, Cas9-mediated knockout of TP53 in 158 MCF10A cells also caused no significant effect on basal or PMA-induced A3B expression levels 159 ( Fig. 3C-D) . These data combine to indicate that TP53 has no significant role in the 160 transcriptional regulation of A3B, disproving our original hypothesis (21) and conflicting with 161 recently published data (33) (Discussion). 162 163 RB-family knockdown is insufficient to induce APOBEC3B expression. RB1 is the most 164 widely studied target of the LXCXE motif of viral proteins such as HPV E7, adenovirus E1A, 165 and polyomavirus LTAg (29, 30, 35, 36) . Due to the structural conservation of the LXCXE-166 binding clefts in other pocket proteins, RBL1 (p107) and RBL2 (p130) are also efficiently 167 targeted for degradation by LTAg and truncT and may be important for A3B regulation (37) (38) (39) (40) . 168 with siRNAs targeting each of these factors in RPTECs and MCF10A ( Fig. 4A-B) . showed that >75% knockdown was achieved for each targeted gene (upper panels in Fig. 4A-B) . 174
As controls, CCNE2 was upregulated upon RB1 knockdown and UNG2 was upregulated by 175 RBL2 knockdown (lower panels in Fig. 4A-B ). However, surprisingly, no combination of 176 siRNAs resulted in significant A3B upregulation (lower panels in Fig. 4A-B) . These results 177 indicate that depletion of RB family members is alone insufficient to upregulate A3B, at least in 178 these two different normal-like cell types where A3B can be induced. These results also suggest 179 that truncT in aforementioned experiments may have at least one additional activity mediated the 180 LXCXE motif that contributes to A3B upregulation. 181 182 Pharmacological inhibition of CKD4/6 does not alter APOBEC3B expression. Palbociclib is 183 a selective inhibitor of CDK4 and CDK6, which are kinases that function normally to 184 phosphorylate RB, prevent binding to E2F transcription factors, and stimulate the expression of 185 many genes involved in cell cycle progression (41) (42) (43) . To corroborate the knockdown 186 experiments above we treated a panel of transformed cell lines with palbociclib and quantified 187 mRNA expression levels over time. This diverse cell panel was constructed based on A3B 188 expression, ranging from low to high (44, 45), TP53 status, and ability to phosphorylate RB. As 189 a positive control for palbociclib efficacy we analyzed expression of CCNE2, which encodes 190
Cyclin E2, promotes entry into S phase, and is a known CDK4/6-RB regulated gene (46, 47) . 191 9 The majority of cell lines showed a dose-and time-responsive decrease in CCNE2 expression 192 ( Fig. 5A) . This effect was minimal in HCC1937 and HCC1599 cells, which are known to display 193 decreased RB phosphorylation (48, 49) . In contrast, none of the palbociclib treated cell lines 194 showed a reproducible or significant change in A3B mRNA expression. In addition, MCF10A 195 cells were treated with PMA to induce A3B mRNA expression by the PKC/ncNF-κB pathway 196 and, again, palbociclib had little effect ( Fig. 5B-C , palbociclib added post-or pre-PMA addition, 197 respectively). These results combine to indicate that the kinase activity of CDK4 and CDK6 is 198 dispensable for A3B expression in multiple different cell lines. 199
200
Cancer transcriptome analyses support involvement of RB-pathway in APOBEC3B 201 regulation. We next used bioinformatics approaches to mine TCGA data and assess global 202 correlates with A3B expression in human tumors. First, we conducted pathway analysis using all 203 genes with significant positive correlations between A3B expression in TCGA breast cancer 204 cohort. This analysis revealed that half of the top 20 significantly enriched upstream transcription 205 factors contributing to this expression pattern are part of the CDK4/6-Cyclin D-RB-E2F axis 206 (green-labeled genes in Fig. 6A ). These regulators were either significantly activated or 207 inhibited, generally corresponding with known functions, with the net outcome being accelerated 208 cell cycling (respectively, red and blue colored bars in Fig. 6A ). Upon closer pair-wise 209 examination of effectors in this signal transduction pathway, A3B mRNA expression has the 210 strongest positive correlations with expression of RBL1, E2F1, E2F2, E2F7, and E2F8 (Fig. 6B) . 211
Lastly, we expanded this expression correlation analysis to 22 cancer types in TCGA and all 11 212 APOBEC family members. This global approach further highlighted strong correlations between 213 A3B and expression of E2F1, E2F2, E2F7, and E2F8, and indicated that the association between 214
Discussion

219
In this study, we investigate the mechanism of A3B upregulation by polyomavirus T antigen 220 through separation-of-function mutants, genetic knockdowns, and bioinformatics approaches. 221
First, we use high-resolution fluorescent microscopy to show that polyomavirus infection causes 222 A3B upregulation and protein accumulation in the nuclear compartment. Second, we show that 223 the LXCXE motif of LTAg and truncT, which is well known to inhibit the tumor suppressor RB, 224
is essential for A3B upregulation, whereas the TP53-binding domain is dispensable. Third, 225 genetic and pharmacologic treatments indicate that RB family members (RB, RBL1, and RBL2) 226 and activity from kinases responsible for their phosphorylation (CDK4 and CDK6) are 227 dispensable for A3B mRNA upregulation. However, bioinformatics analyses of tumor expression 228 data show strong global correlations between A3B mRNA expression and expression of other 229 genes regulated by the RB-E2F signaling pathway including several members of the E2F family 230 of transcription factors. Taken together, these results indicate that this pathway, which is 231 commonly modified in cancer, contributes to A3B gene expression and, once 232 upregulated/activated, then A3B expression appears capable of continuing without additional 233 signaling from this pathway (model in Fig. 7) . 234
Our original studies with HPV and A3B led us to propose a model in which TP53 235
represses A3B transcription and that TP53 inactivation by the viral oncoprotein E6 or by genetic 236 mutation results in derepression of A3B transcription (50) . This transcription repression model is 237 genetic approaches to provide further support for such a transcriptional model (33). However, 240 three different results here do not support this TP53-mediated model for A3B repression. 241
Specifically, the TP53 binding domain of BKPyV is dispensable for A3B upregulation, nutlin 242 treatment has no effect on basal or induced A3B expression, and TP53 knockout fails to induce 243 A3B expression ( Fig. 2 and Fig. 3) . Moreover, another recent study showed that TP53 244 inactivation renders cells more permissive for A3B overexpression and mutagenesis (45). 245
Therefore, we now favor a "tolerance model" in which TP53 inactivation (genetic, epigenetic, or 246 viral) is required for cells to be able to tolerate A3B overexpression. This model also explains 247 why TP53 mutation is the only clear global correlate with A3B overexpression in cancer. 248
The RB-E2F signaling pathway is one of the most frequently mutated in cancer, which 249 contributes to several hallmarks of cancer by deregulating the cell cycle (51). RB-inactivation is 250 also a common target for viral genes in order to promote the survival of infected cells. The 251 integration and continued expression of these genes in the host genome are common 252 characteristics of virus-associated tumors. For example, HPV-associated tumors frequently have 253 genetically conserved copies of the E7 oncogene integrated into the tumor genome that are 254 critical for tumor development (52). These tumors also tend to have a high burden of APOBEC-255 associated mutations predominantly on the lagging strand, which is synthesized during the S--256 phase (12, 15, 53) . Although some of these effects have been explained by perturbations to the 257 TP53 pathway, other pathways have also been shown to alter A3B expression (23, 27, 33, 50) . It 258 is therefore not surprising in hindsight that expression of the antiviral enzyme, A3B, is also 259 induced when the RB-E2F pathway is disrupted. Furthermore, previous studies also observed 260 12 that elevated A3B expression is significantly correlated with proliferative features in breast 261 cancer (54). Together this suggests a complex network of A3B regulation, to prevent potentially 262 oncogenic mutations of the host genome during normal cellular replication, while activating the 263 enzyme during abnormal cell cycling due to viral infection or cancer. expressing TAg, and mutants were produced in 293T cells and transduced into RPTE cells as 275 described previously (21). BKPyV infections were conducted in MCF10A cells as described 276 previously in RPTECs (55). 277 278 Antibodies. The pAb416 antibody was used against BK T-antigen, which detects both Large T 279 and truncT (28). PAB2000 was used against JC large T-antigens and mutants (56). Harris lab 280 manufactured rabbit monoclonal antibody 10.87.13 was used to detect APOBEC3B (57). UNG2 281 was detected using the Abcam antibody #23926. 282 and resuspension in TRIzol (Thermo Fisher), and purification was done per the manufacturer's 285 protocol. Reverse transcription-quantitative PCR (RT-qPCR) was used to quantify A3 transcripts 286 as described previously (21). Protein lysates were harvested at 7 days post infection (dpi) or 3 287 days post transduction, quantified, and immunoblotted as described previously (55). 288 289 Immunofluorescence. HuK(i)G10 kidney cells were seeded at 6000 cells/well in a 96-well 290 plate. 24 hours later, infection with JCPyV was performed as previously described and then cells 291 were collected 7 days post infection. Infected cells were incubated with EdU (Click-iT Plus EdU 292
Alexa Fluor 647 Imaging Kit, Thermo Fisher Scientific) for 15 min and incubated with CSK 293 buffer (10 mM Hepes-KOH, pH 7.4; 300 mM sucrose; 100 mM NaCl; 3 mM KCL; 0.5% triton 294
x-100) (58) for 2 min on ice. Cells were then fixed in 4% PFA for 10 min followed by 295 permeabilization with 0.5% Triton x-100 for 20 min. For EdU detection, the Click-iT reagent 296 was added for 30 min in the dark following manufacturers protocol and washed 3x with PBS. 297
Samples were incubated with BlockAid blocking solution (Thermo Fisher) for 1 hour at RT. T-298 antigen, VP1 and A3B staining were performed using the aforementioned antibodies at 1:1000, 299 1:1000 and 1:100 dilutions in BlockAid, respectively, overnight at 4°C followed by staining with 300 the secondary antibodies for 1h at RT. Images were acquired on the Phenix with the confocal 301 63x water objective. palbociclib was added to cells of the 0h time point, which instead was transferred to ice prior to 320 RNA isolation. RNA was also isolated at 1h and 8 h post palbociclib administration (Total RNA 321
Purification Kit 37500, Norgen), and cDNA was synthesized with 500ng RNA (iScript, 170-322 8891, Bio-Rad). RT-qPCR assays for A3B and CCNE2 were performed using the C1000 TM 323
Thermal Cycler (Bio-Rad). For pre-treatment with PMA, cells were treated with 0 or 25ng/ml 324 PMA for 3 hours, followed by treatment with 0µM, 0.5µM, and 2.5µM palbociclib. RNA was 325 isolated at 0, 1, and 3 hours, and processed as described above. Pre-treatment with palbociclib 326 included a 0, 1, or 3 hour treatment with 0 or 25ng/ml PMA, added to cells which had been 327 treated with 0µM, 0.5µM, and 2.5µM palbociclib 30 minutes earlier. RNA was isolated at 0, 1, 328 and 3 hours post PMA addition, and processed as described above. 329 cancer cohort were calculated and significant correlates were used to determine significant 333 activation or inhibition of upstream regulators using Ingenuity Pathway Analysis (Qiagen). All 334 other Spearman correlations and p-values were calculated and heatmaps were plotted using the R 335 statistical environment. BRCA  HNSC  BLCA  CESC  KIRP  LUAD  LUSC  READ  LAML  ESCA  LGG  LIHC  PAAD  PRAD  SARC  STAD  TGCT  THCA  UCEC  SKCM   OV  BRCA  HNSC  BLCA  CESC  KIRP  LUAD  LUSC  READ  LAML  ESCA  GBM   GBM   GBM  LGG  LIHC  PAAD  PRAD  SARC  STAD  TGCT  THCA  UCEC  SKCM  OV  BRCA  HNSC  BLCA  CESC  KIRP  LUAD  LUSC  READ  LAML  ESCA  LGG  LIHC  PAAD  PRAD  SARC  STAD  TGCT  THCA  UCEC  SKCM   E2F1  E2F2  E2F3  E2F4  E2F5  E2F6  E2F7  E2F8  RB1  RBL1  RBL2  E2F1  E2F2  E2F3  E2F4  E2F5  E2F6  E2F7  E2F8  RB1  RBL1  RBL2  E2F1  E2F2  E2F3  E2F4  E2F5  E2F6  E2F7  E2F8  RB1  RBL1  RBL2  E2F1  E2F2  E2F3  E2F4  E2F5  E2F6  E2F7  E2F8  RB1  RBL1 
